• Eligible subjects selected for this study must meet all of the following criteria:

‣ Sign written informed consent before implementing any trial-related procedures;

⁃ Age ≥18 years old;

⁃ No limit on the gender;

⁃ Histological or cytological confirmed advanced or metastatic non-small cell lung cancer, ineligible for radical surgery, relapse after failure of previous treatment with first-line (including first, second, and third generation)EGFR inhibitors.

‣ Cohort A：MET amplification,(by FISH, NGS or IHC) Cohort B：RET fusion.

⁃ Laboratory tests for organ function levels must meet the following requirements:

• Absolute neutrophil count ≥ 1.5 × 109/L;

∙ Platelet count ≥ 100 × 109/L;

∙ Hemoglobin ≥ 9 g/dL;

∙ Bilirubin ≤1.5 times ULN; e) AST and ALT ≤2.5 times ULN (total bilirubin ≤3 times the upper limit of normal and AST and ALT ≤5 times the upper limit of normal are permitted if hepatic metastases are present);

‣ f) Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60 mL/min (according to the Cockcroft-Gault formula);

⁃ For premenopausal women of childbearing potential a pregnancy test must be performed within 7 days prior to initiation of treatment, a serum pregnancy test must be negative, and they must be non-lactating; all enrolled patients (whether male or female) should use adequate barrier contraception throughout the treatment period and for 3 months after completion of treatment.